	US 7,482,487 B2
	Phenylaminoethanol derivatives as β2 receptor agonists
Alan Daniel Brown, Sandwich (United Kingdom); Justin Stephen Bryans, Sandwich (United Kingdom); Paul Alan Glossop, Sandwich (United Kingdom); Charlotte Alice Louise Lane, Sandwich (United Kingdom); and Simmon John Mantell, Sandwich (United Kingdom)
Assigned to Pfizer Inc, New York, N.Y. (US)
Appl. No. 10/598,843 PCT Filed Mar. 10, 2005, PCT No. PCT/IB2005/000611 § 371(c)(1), (2), (4) Date Jun. 15, 2007, PCT Pub. No. WO2005/090288, PCT Pub. Date Sep. 29, 2005.
Claims priority of provisional application 60/591854, filed on Jul. 27, 2004.
Claims priority of application No. 04290724 (EP), filed on Mar. 17, 2004; and application No. 05708707 (EP), filed on Mar. 10, 2005.
Prior Publication US 2007/0264262 A1, Nov. 15, 2007
Int. Cl. C07C 233/05 (2006.01); A61K 31/65 (2006.01)

U.S. Cl. 564—165 [514/595; 514/596; 514/616; 514/620; 564/48; 564/56; 564/86; 564/155; 564/158]

12 Claims

1. A compound of formula (1):

wherein the CH₂—C(═O)NH-benzyl-Q¹-Q²-Q³-Q⁴group is in the meta or para position;

R¹and R²are independently selected from H and C₁-C₄alkyl;

Q¹is —(CH₂)_n—;

n is 0 or 1;

Q²is selected from —NH—, —C(═O)NH—, —NHC(═O)—, —NH—C(═O)—NH—, and —SO₂NH—;

Q³is a single bond or a C₁-C₄alkylene optionally substituted with OH;

Q⁴is selected from

wherein * represents the attachment point to Q³;

R³, R⁴, R⁵, R⁶and R⁷are independently selected from H, C₁-C₄alkyl, phenyl, phenoxy, OR⁸, SR⁸, halo, CN, CF₃, OCF₃, COOR⁹, SO₂NR⁸R⁹, CONR⁸R⁹, NR⁸R⁹, NHCOR⁹and CH₂—NHC(═O)NH—R⁹; and

R⁸and R⁹are independently selected from H and C₁-C₄alkyl; or a pharmaceutically acceptable salt, isomer, tautomer, solvate or isotopic variation thereof.